UBS/CALL/IDORSIA/10.008/0.125/20.09.24 Stock

UBS/CALL/IDORSIA/10.008/0.125/20.09.24 Share Price

Warrant

NIDI6U

CH1250694127

Market Closed - Swiss Exchange 16:20:00 23/02/2024 GMT
0.08 ^CHF	+100.00%

Current year

+100.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/10.008/0.125/20.09.24

Latest news about IDORSIA LTD

New semester, new state of mind	12:00pm
Idorsia Wins European Commission's Nod for Resistant Hypertension Treatment	09:06am	MT
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension	06:00am	GL
Idorsia Ltd Receives Approval from the European Commission for JERAYGO?	06:00am	CI

More news

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	NIDI6U
ISIN	CH1250694127
Date issued	03/04/2023
Strike	10.01 CHF
Maturity	20/09/2024 (81 Days)
Parity	8 : 1
Emission price	0.42 CHF
Emission volume	N/A
Settlement	physique
Currency	CHF

Technical Indicators

Highest since issue	0.39 CHF
Lowest since issue	0.02 CHF
Delta	0x
Omega	0.000000
Premium	0x
Gearing	0x
Moneyness	0.2142
Difference Strike	7.908 CHF
Difference Strike %	+79.02%
Intrinsic value	0.000000

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company